
|Articles|August 13, 2008
FDA warns of adverse reactions to naltrexone
The FDA said patients should monitor the injection site.
Advertisement
The Food and Drug Administration is
The FDA said patients should monitor the injection site and contact a physician if they develop pain, swelling, tenderness, induration, bruising, pruritus, or redness that does not improve or worsens within two weeks.
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
2
Q&A: Pharmacists Can Address ADA Standards Across All Settings
3
Executive Order Calls for Realignment of Childhood Vaccines
4
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
5





























































